IRUS Total

The use of faecal microbiota transplantation (FMT) in Europe: a Europe-wide survey

File Description SizeFormat 
1-s2.0-S2666776221001587-main.pdfPublished version679.27 kBAdobe PDFView/Open
Title: The use of faecal microbiota transplantation (FMT) in Europe: a Europe-wide survey
Authors: Baunwall, SMD
Terveer, EM
Dahlerup, JF
Erikstrup, C
Vehreschild, MJGT
Ianiro, G
Gasbarrini, A
Sokol, H
Kump, PK
Satokari, R
De Looze, D
Vermeire, S
Nakov, R
Brezina, J
Helms, M
Kjeldsen, J
Rode, AA
Kousgaard, SJ
Alric, L
Trang-Poisson, C
Scanzi, J
Link, A
Stallmach, A
Kupcinskas, J
Johnsen, PH
Garborg, K
Sánchez-Rodríguez, E
Serrander, L
Brummer, RJ
Galpérine, KT
Goldenberg, SD
Mullish, BH
Williams, HRT
Iqbal, TH
Ponsioen, C
Kuijper, EJ
Cammarota, G
Keller, JJ
Hvas, CL
Item Type: Journal Article
Abstract: Background Faecal microbiota transplantation (FMT) is an emerging treatment modality, but its current clinical use and organisation are unknown. We aimed to describe the clinical use, conduct, and potential for FMT in Europe. Methods We invited all hospital-based FMT centres within the European Council member states to answer a web-based questionnaire covering their clinical activities, organisation, and regulation of FMT in 2019. Responders were identified from trials registered at clinicaltrials.gov and from the United European Gastroenterology (UEG) working group for stool banking and FMT. Findings In 2019, 31 FMT centres from 17 countries reported a total of 1,874 (median 25, quartile 10–64) FMT procedures; 1,077 (57%) with Clostridioides difficile infection (CDI) as indication, 791 (42%) with experimental indications, and 6 (0•3%) unaccounted for. Adjusted to population size, 0•257 per 100,000 population received FMT for CDI and 0•189 per 100,000 population for experimental indications. With estimated 12,400 (6,100–28,500) annual cases of multiple, recurrent CDI and indication for FMT in Europe, the current European FMT activity covers approximately 10% of the patients with indication. The participating centres demonstrated high safety standards and adherence to international consensus guidelines. Formal or informal regulation from health authorities was present at 21 (68%) centres. Interpretation FMT is a widespread routine treatment for multiple, recurrent CDI and an experimental treatment. Embedded within hospital settings, FMT centres operate with high standards across Europe to provide safe FMT. A significant gap in FMT coverage suggests the need to raise clinical awareness and increase the FMT activity in Europe by at least 10-fold to meet the true, indicated need. Funding NordForsk under the Nordic Council and Innovation Fund Denmark (j.no. 8056–00006B).
Issue Date: 1-Oct-2021
Date of Acceptance: 2-Jul-2021
URI: http://hdl.handle.net/10044/1/90650
DOI: 10.1016/j.lanepe.2021.100181
ISSN: 2666-7762
Publisher: Elsevier
Journal / Book Title: The Lancet Regional Health - Europe
Volume: 9
Copyright Statement: © 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Sponsor/Funder: Imperial College Healthcare NHS Trust- BRC Funding
Imperial College Healthcare NHS Trust- BRC Funding
Funder's Grant Number: RDA27
Publication Status: Published
Article Number: ARTN 100181
Online Publication Date: 2021-07-19
Appears in Collections:Department of Metabolism, Digestion and Reproduction
Faculty of Medicine

This item is licensed under a Creative Commons License Creative Commons